Q-omics provides the consensus-scored ITPKB-AS1 profile across patient tissues and cancer cell-line models. ITPKB-AS1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ITPKB-AS1 is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, ITPKB-AS1 RNA expression shows 11,079 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and UCEC as cancer lineages where ITPKB-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITPKB-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITPKB-AS1 survival associations across molecular data types. ITPKB-AS1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITPKB-AS1 RNA expression–survival associations across cancer types. High ITPKB-AS1 expression shows unfavorable associations in LUSC, but favorable associations in HNSC, STAD, UCS, MESO and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify HNSC as the clearest survival context for ITPKB-AS1 RNA expression.
This table summarizes ITPKB-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for ITPKB-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITPKB-AS1 shows lower tumor expression in UCEC, READ, COAD, LUSC and KICH. The UCEC box plot shows higher ITPKB-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.590, t-test p = .002).
This table shows molecular features associated with ITPKB-AS1 in patient tissues and cancer cell lines. In patient samples, ITPKB-AS1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
